Wockhardt has received a communication from the Medicines and Healthcare Products Regulatory Agency, United Kingdom (UKMHRA), whereby the agency has allowed the company to manufacture and supply most of the products manufactured at Survey No 406/4-5-7, Kadaiya, Nani Daman facility and assessed to be critical to public health.
The company had earlier on October 22, 2013 received communication from UKMHRA, whereby the agency had decided to withdraw the previously issued GMP Certificate to the said manufacturing facility.
As a result the net impact on the annualised consolidated revenue is expected to be less than £1 million, out of the total annual consolidated revenue of approximately £18 million, from the said facility.
